EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Extended field periaortic irradiation in carcinoma of the prostate analysis of radiotherapy and oncology group 75 06






International Journal of Radiation Oncology, Biology, Physics 12(3): 345-352

Extended field periaortic irradiation in carcinoma of the prostate analysis of radiotherapy and oncology group 75 06

From 1976 to 1983 the Radiation Therapy Oncology Group conducted a study of extended field (periaortic) irradiation in carcinoma of the prostate. Eligible patients were those with clinical Stage C tumor with or without evidence of pelvic lymph node involvement and also those with Stage A-2 and B with evidence of pelvic lymph node involvement. The stratification criteria included histological grade, clinical stage, absence or presence of hormonal manipulation, and method of lymph node evaluation (lymphangiogram vs. laparotomy vs. no nodal evaluation). The patients were randomized to either receive pelvic irradiation followed by a boost to the prostate or pelvic and periaortic irradiation followed by a boost to the prostate. The prescribed daily dose was 180-200 rad to a total midplane dose to the regional lymphatics to 4000-4500 rad. The prostatic boost target volume was to receive additional 2000-2500 rad bringing the total dose to that area to a minimum of 6500 rad. A total of 523 analyzable patients have been accessioned to the protocol. Four hundred forty-eight of these are known to have received treatment per protocol. Median follow-up is 4 years and 3 months. The analyzable patients were evaluated for the incidence of distant metastases, NED survival and survival as a function of treatment arm. No statistically significant differences between the treatment arms could be documented. Similarly, no significant difference between treatment arms could be documented within a number of subpopulations such as those characterized by a particular grade, hormonal status, stage, age, acid phosphatase level, etc. The results of the study revealed no apparent benefit of elective periaortic irradiation in patients with detectable disease confined to the pelvis.

(PDF 0-2 workdays service: $29.90)

Accession: 005432584



Related references

Extended field (periaortic) irradiation in carcinoma of the prostate--analysis of RTOG 75-06. International Journal of Radiation Oncology, Biology, Physics 12(3): 345-351, 1986

Preliminary report on phase iii radiation therapy oncology group studies on extended field irradiation in carcinoma of the prostate. American Journal of Clinical Oncology 6(4): 485-492, 1983

Preliminary report on phase iii radiation therapy oncology group studies of extended field irradiation in carcinoma of the prostate. American Journal of Clinical Oncology 5(2): 140-141, 1982

Treatment related morbidity in phase iii radiation therapy and oncology group studies of extended field irradiation for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics 10(10): 1861-1868, 1984

Phase iii radiation therapy oncology group study of extended field peri aortic irradiation in patients with carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics 10(SUPPL 2): 117, 1984

Treatment related morbidity in the phase iii radiation therapy oncology group studies of extended field irradiation in carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics 8(SUPPL 1): 124, 1982

Extended field irradiation for carcinoma of the uterine cervix with positive periaortic nodes. International Journal of Radiation Oncology, Biology, Physics 23(3): 501-509, 1992

Phase iii study on the treatment of women with cervical cancer stage iib iiib and iva confined to the pelvis and or periaortic nodes with radiotherapy alone versus radiotherapy plus immunotherapy with intravenous corynebacterium parvum a gynecologic oncology group study. Gynecologic Oncology 26(3): 386-397, 1987

Radical radiotherapy for carcinoma of the prostate: localized and extended field treatment. Australian and New Zealand Journal of Surgery 53(6): 561-565, 1983

Post-operative irradiation of prostate carcinoma Results of the Italian survey performed by the AIRO National Working Group on Prostate Radiotherapy. EJC Supplements 1(5): S256-S257, September, 2003